GlassScriptPhysician profile
Ather Mehboob
NPI 1427116763
$3,908.43
in general payments reported to CMS, 2019-2025
39 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $895 · 2021: $634 · 2022: $414 · 2023: $324 · 2024: $235 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.52 |
| Education | $251.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $749.54 | 2019-2024 | Opdivo |
| Pfizer INC. | $393.91 | 2019-2024 | |
| Amgen INC. | $318.02 | 2019-2022 | |
| Janssen Biotech, INC. | $307.19 | 2019-2024 | Darzalex |
| Daiichi Sankyo INC. | $237.10 | 2019-2025 | Injectafer, Vanflyta |
| Genentech USA, INC. | $230.09 | 2019-2024 | Phesgo |
| Astrazeneca Pharmaceuticals LP | $188.22 | 2020-2025 | Imfinzi |
| Astellas Pharma US INC | $150.27 | 2023-2025 | Vyloy, Xospata, Padcev |
| Eisai INC. | $142.88 | 2020-2022 | |
| Exelixis INC. | $135.90 | 2019-2022 | |
| Seagen INC. | $117.89 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $109.41 | 2019-2025 | Keytruda, Keytruda Qlex |
| Lilly USA, LLC | $102.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $83.07 | 2019-2023 | |
| Genzyme Corporation | $70.83 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ather Mehboob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.